Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.

Autor: McKnight BN; Department of Oncology, Karmanos Cancer Institute Wayne State University, 4100 John R Street, Detroit, MI, 48201, USA., Kim S; Department of Oncology, Biostatistics Core, Karmanos Cancer Institute Wayne State University, Detroit, MI, 48201, USA., Boerner JL; Department of Oncology, Karmanos Cancer Institute Wayne State University, 4100 John R Street, Detroit, MI, 48201, USA., Viola NT; Department of Oncology, Karmanos Cancer Institute Wayne State University, 4100 John R Street, Detroit, MI, 48201, USA. violan@karmanos.org.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2020 Apr 15; Vol. 22 (1), pp. 37. Date of Electronic Publication: 2020 Apr 15.

IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.

Autor: Gibson HM; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan., McKnight BN; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan., Malysa A; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan., Dyson G; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan., Wiesend WN; Department of Anatomic Pathology, Beaumont Health System, Royal Oak, Michigan., McCarthy CE; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan., Reyes J; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan., Wei WZ; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan. villegan@karmanos.org weiw@karmanos.org., Viola-Villegas NT; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan. villegan@karmanos.org weiw@karmanos.org.

Publikováno v: Cancer research [Cancer Res] 2018 Oct 01; Vol. 78 (19), pp. 5706-5717. Date of Electronic Publication: 2018 Aug 16.

Imaging EGFR and HER3 through ⁸⁹ Zr-labeled MEHD7945A (Duligotuzumab).

Autor: McKnight BN; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA., Kuda-Wedagedara ANW; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA., Sevak KK; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA., Abdel-Atti D; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA., Wiesend WN; Department of Anatomic Pathology, Beaumont Hospital, 3601 West 13 Mile Road, Royal Oak, MI, 48073, USA., Ku A; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA., Selvakumar D; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA., Carlin SD; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA., Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.; Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA., Viola-Villegas NT; Department of Oncology, Karmanos Cancer Institute, 4100 John R. Street, Detroit, MI, 48201, USA. villegan@karmanos.org.; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. villegan@karmanos.org.

Publikováno v: Scientific reports [Sci Rep] 2018 Jun 13; Vol. 8 (1), pp. 9043. Date of Electronic Publication: 2018 Jun 13.